Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the first/most general mortality aspect is supported by the provided label excerpts. Claims about longer treatment duration increasing mortality, and antibiotic resistance as a consequence of prolonged tigecycline/antibiotic use, are not supported by the supplied labeling text.
Category Scores
Accurate Statements
TYGACIL is associated with increased all-cause mortality compared with comparator drugs in clinical trials.
Supported by label text in 5.1 All-Cause Mortality and reiterated in 6.1 Clinical Trials Experience (death 4.0% vs 3.0%; adjusted risk difference 0.6% (95% CI 0.1, 1.2)).
Unsupported Statements
Longer duration of tigecycline treatment was associated with reduced survival rates in patients with severe infections.
The provided label excerpts discuss all-cause mortality and a specific hospital/ventilator-associated pneumonia trial, but do not support an association between treatment duration (e.g., longer duration) and survival reduced outcomes.
Patients with severe infections who received tigecycline for more than 7 days had significantly higher mortality rates than those who received tigecycline for 7 days or less.
The provided label excerpts do not provide any data stratified by a 7-day treatment threshold or report 'more than 7 days' vs '7 days or less' mortality.
Prolonged tigecycline treatment may contribute to the development of antibiotic resistance.
The provided label excerpts do not mention tigecycline-related or duration-related antibiotic resistance development.
Antibiotic resistance can compromise patient outcomes.
The provided label excerpts do not state that antibiotic resistance compromises patient outcomes.
Prolonged use of antibiotics like tigecycline can lead to the emergence of resistant bacterial strains.
The provided label excerpts do not state that prolonged antibiotic use (specifically tigecycline) leads to resistant bacterial strain emergence.
Contradictions
Important Omissions
When discussing increased mortality, the provided label excerpts also emphasize that the cause has not been established and that deaths generally resulted from worsening infection/complications/underlying comorbidities, and include a specific limitation that TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia with associated greater mortality/decreased efficacy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements attribute mortality effects to longer duration and connect prolonged use to antibiotic resistance, neither of which are supported by the provided prescribing information excerpts. While not directly contradicting mortality warnings, unsupported mechanistic/duration claims could mislead interpretation of risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported claims regarding treatment duration thresholds (e.g., >7 days) and antibiotic resistance outcomes are not supported by the supplied label text.
Suggested Improvement
Restrict mortality claims to the label-supported findings: increased all-cause mortality in comparator-controlled Phase 3/4 trials with reported death rates and adjusted risk difference, and (if discussed) the label’s specific hospital/ventilator-associated pneumonia context and limitation of use. Avoid duration-threshold and resistance claims unless supported by additional label sections not provided here.